Cardium Therapeutics has chosen Cedars-Sinai Medical Center Nuclear Cardiology Core Laboratory in Los Angeles to serve as the central core lab for its Generx ASPIRE clinical study.
Cedars-Sinai will consolidate and analyze SPECT myocardial imaging data from Russian medical centers participating in the trial, which is designed to study perfusion blood-flow defect size as measured by SPECT imaging.
The Core Laboratory is led by Dr. Daniel Berman, head of nuclear cardiology at Cedars-Sinai Medical Center and associate director for cardiac imaging at the Cedars-Sinai Heart Institute.
